Pfizer (NYSE:PFE) received mixed analyst ratings in the last quarter with 9 analysts offering a range of views. The average 12-month price target is $37.33, reflecting a 1.8% increase from the previous target. Analyst actions include maintaining, announcing, and lowering ratings with price targets ranging from $27.00 to $45.00. Pfizer's financials show challenges in revenue growth, net margin, ROE, and ROA, but it maintains a balanced debt approach. The company's market cap is above industry averages, despite a -41.34% revenue decline over 3 months.